Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00746759 · ClinicalTrials.gov registry record
Airway Epithelium Gene Expression: AEGIS IDE
A clinical trial, sponsored by Allegro Diagnostics.
- Completed
- Registry status
- 1,331
- Enrollment target
NCT00746759: Completed study, sponsored by Allegro Diagnostics.
NCT00746759 is a clinical trial that has completed, run by Allegro Diagnostics. The registered enrollment target is 1,331 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00746759 has completed, sponsored by Allegro Diagnostics.
- COMPLETED
- Registry status
- 1,331 participants
- Enrollment target
Study Summary
The purpose of the research study is to develop a new, more sensitive, and less invasive test for diagnosing lung cancer at an earlier stage, when it can more easily be cured. The investigators hypothesize that certain genes are expressed differently in current and former smokers who have lung cancer, and this difference in gene expression may be a biomarker for lung cancer.
Interventions
- DEVICE Biomarker (not used as an intervention)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,331 participants |
| Start Date | 2010-02 |
| Est. Completion | 2015-02 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00746759
The ClinicalTrials.gov registry entry for NCT00746759 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 1,331 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allegro Diagnostics, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Biomarker (not used as an intervention) is the first listed.
NCT00746759 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00746759 about?
NCT00746759 is a clinical study titled "Airway Epithelium Gene Expression: AEGIS IDE". The purpose of the research study is to develop a new, more sensitive, and less invasive test for diagnosing lung cancer at an earlier stage, when it can more easily be cured. The investigators hypothesize that certain genes are expressed differently in current and former smokers who have lung cance...
What is the current status of trial NCT00746759?
This trial is currently completed. The enrollment target is 1,331 participants. The study started on 2010-02. Estimated completion is 2015-02.
What interventions are being tested in trial NCT00746759?
The interventions under investigation include: Biomarker (not used as an intervention) (DEVICE).
Who is sponsoring clinical trial NCT00746759?
This trial is sponsored by Allegro Diagnostics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.